Recro Pharma, Inc. (NASDAQ:REPH) will be issuing its quarterly earnings data on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.06. Recro Pharma had a negative net margin of 46.75% and a negative return on equity of 56.04%. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $14.90 million. On average, analysts expect Recro Pharma to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of Recro Pharma, Inc. (REPH) opened at $8.75 on Tuesday. Recro Pharma, Inc. has a 1-year low of $5.81 and a 1-year high of $10.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 5.81 and a quick ratio of 5.23.

An institutional investor recently bought a new position in Recro Pharma stock. California State Teachers Retirement System acquired a new stake in shares of Recro Pharma, Inc. (NASDAQ:REPH) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 24,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $169,000. California State Teachers Retirement System owned 0.13% of Recro Pharma at the end of the most recent quarter. 65.25% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Recro Pharma, Inc. (REPH) to Release Quarterly Earnings on Wednesday” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at

A number of brokerages have issued reports on REPH. Zacks Investment Research downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, August 31st. Roth Capital set a $20.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st. Finally, Piper Jaffray Companies set a $11.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Tuesday, July 25th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $12.63.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Earnings History for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with's FREE daily email newsletter.